Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

U.S. FDA advisers recommend change to COVID vaccine composition for fall

Stock Markets Jun 29, 2022 08:11AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
3/3 © Reuters. FILE PHOTO: Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/Illustration 2/3

By Michael Erman and Leroy Leo

(Reuters) -Advisers to the U.S. Food and Drug Administration on Tuesday recommended a change in the design of COVID-19 booster shots this fall in order to combat more recently circulating variants of the coronavirus.

The FDA's Vaccines and Related Biological Products Advisory Committee voted 19-2 that the next wave of COVID booster shots should include a component that targets the Omicron variant of the coronavirus.

The FDA plans to decide by early July on what the design of the boosters should be.

FDA scientists at the meeting suggested they preferred vaccines that will target the BA.4 and BA.5 Omicron subvariants that are currently dominant rather than the BA.1 Omicron variant that led to a massive surge in infections last winter.

Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said the regulator would hope to launch a booster campaign with a retooled vaccine by October.

"The better the match of the vaccines to the circulating strain we believe may correspond to improved vaccine effectiveness, and potentially to a better durability of protection," Marks told the meeting of outside expert advisers to the agency.

Pfizer Inc (NYSE:PFE), Moderna (NASDAQ:MRNA) Inc and Novavax (NASDAQ:NVAX) Inc presented data at the meeting. All three companies have been testing versions of their vaccines updated to combat the BA.1 Omicron variant.

Moderna said it would be ready with a "couple of hundred million" of bivalent, or double targeted, vaccines designed to combat BA.1 by September. It would be late October or early November if it needs to design a vaccine targeting the newer subvariants, the company said.

Pfizer said that it and partner BioNTech already has a significant amount of BA.1 vaccine ready and is preparing to produce a large amount of vaccine targeting BA.4 and BA.5. It said either could be ready for an early October rollout.

Dr. Kanta Subbarao, representing a World Health Organization advisory committee that also considered the issue, said she preferred BA.1-based vaccines, suggesting they could generate a broader immune response because that variant is more distinct from the original virus than its successor subvariants.

"Our goal here is to achieve broader immunity against circulating and emerging variants," Subbarao said, noting that trying to match what variant might be circulating in the fall is difficult because of uncertainty about the trajectory of the evolution of the virus.

Both Moderna and Pfizer have said that their respective BA.1 inclusive vaccines generated a better immune response against Omicron than their current shots that were designed for the original virus that emerged from China.

They have said their new vaccines also appear to work against BA.4 and BA.5, but that protection is not as strong as against BA.1.

The International Coalition of Medicines Regulatory Authorities, a group of global drug regulators that includes the FDA, will meet to discuss the issue on Thursday.

U.S. FDA advisers recommend change to COVID vaccine composition for fall
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (3)
Billy Foos
Billy Foos Jun 28, 2022 9:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
In other words, its time for those tax payers to ante up and restock, now that big pharma is government funded
Jeremy Johnson
Jeremy Johnson Jun 28, 2022 10:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
How about not creating the virus in a lab to begin with?!
john smith
john smith Jun 28, 2022 10:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Bingo
John Whitfield
John Whitfield Jun 28, 2022 8:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🙄🙄🙄🙄🙄
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email